Physician profile
Jessica Gerner
NPI 1740834241
$1,938.14
in general payments reported to CMS, 2019-2025
34 companies · $753 in 2025
The $753 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $226 · 2023: $398 · 2024: $561 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,711.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $254.92 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $228.26 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $206.86 | 2022-2025 | |
| Amgen INC. | $163.14 | 2022-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $135.96 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $115.82 | 2023-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $92.00 | 2022-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $80.96 | 2024-2025 | Farxiga, Airsupra |
| Axsome Therapeutics, INC. | $69.86 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $65.29 | 2024-2025 | Cologuard Collection Kit |
| Phadia US INC. | $58.41 | 2022-2025 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.11 | 2023-2024 | Tradjenta |
| Glaxosmithkline, LLC. | $31.85 | 2025 | Shingrix, Arexvy |
| Abbott Laboratories | $29.76 | 2025 | Eterna |
| Inspire Medical Systems, INC. | $29.36 | 2025 | Inspire |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $27.20 | 2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $22.61 | 2025 | Gemtesa |
| Vertos Medical, INC. | $20.94 | 2024 | Mild Device Kit |
| Alnylam Pharmaceuticals INC. | $20.44 | 2024 | Givlaari |
| Vertex Pharmaceuticals Incorporated | $19.30 | 2025 | |
| Phathom Pharmaceuticals, INC. | $18.88 | 2024 | Voquezna |
| Optinose US, INC. | $18.81 | 2024 | |
| Sanofi Pasteur INC. | $18.40 | 2023 | |
| Hologic Sales and Service, LLC | $18.39 | 2025 | Aptima |
| Almatica Pharma LLC | $18.34 | 2023 | Gralise, Loreev Xr |
| Avanir Pharmaceuticals, INC. | $17.89 | 2022 | |
| Indivior INC. | $17.54 | 2025 | Sublocade |
| Dexcom, INC. | $16.86 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $16.81 | 2022 | |
| Edwards Lifesciences Corporation | $15.48 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Exeltis, USA INC. | $14.72 | 2023 | Slynd |
| Amneal Pharmaceuticals LLC | $14.53 | 2024 | Unithroid |
| Vivaquant INC, Dba Rhythm Express | $14.28 | 2025 | Rhythm Express |
| Bayer Healthcare Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Gerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.